Prestige Consumer Healthcare reported $267.14 million in revenue for the quarter ended June 2024, representing a year-over-year decline of 4.4%. EPS of $0.90 for the same period compares to $1.06 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $260.07 million, representing a surprise of +2.72%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.86.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- OTC Healthcare- International
: $34.83 million compared to the $35.94 million average estimate based on three analysts. The reported number represents a change of +5% year over year.Revenues- OTC Healthcare- North American
: $232.32 million versus the three-analyst average estimate of $224.16 million. The reported number represents a year-over-year change of -5.6%.Gross profit- OTC Healthcare- North American
: $126.76 million versus the two-analyst average estimate of $123.36 million.Gross profit- OTC Healthcare- International
: $19.27 million versus $19.76 million estimated by two analysts on average.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>Shares of Prestige Consumer Healthcare have returned -0.5% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
View the Zacks #1 Rank List
Image: Bigstock
Prestige Consumer Healthcare (PBH) Reports Q1 Earnings: What Key Metrics Have to Say
Prestige Consumer Healthcare reported $267.14 million in revenue for the quarter ended June 2024, representing a year-over-year decline of 4.4%. EPS of $0.90 for the same period compares to $1.06 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $260.07 million, representing a surprise of +2.72%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.86.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Prestige Consumer Healthcare here>>>Revenues- OTC Healthcare- International
: $34.83 million compared to the $35.94 million average estimate based on three analysts. The reported number represents a change of +5% year over year.Revenues- OTC Healthcare- North American
: $232.32 million versus the three-analyst average estimate of $224.16 million. The reported number represents a year-over-year change of -5.6%.Gross profit- OTC Healthcare- North American
: $126.76 million versus the two-analyst average estimate of $123.36 million.Gross profit- OTC Healthcare- International
: $19.27 million versus $19.76 million estimated by two analysts on average.Shares of Prestige Consumer Healthcare have returned -0.5% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.